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Visceral leishmaniasis (VL) is a vector-borne disease transmitted by phlebotomine sand flies
and remains the most serious form of the disease with no available human vaccine. Repeat-
edly, studies have demonstrated the immunogenicity and protective efficacy of a number
of sand fly salivary proteins against cutaneous and visceral leishmaniasis. All Leishmania
species including agents of VL are co-deposited into the skin together with vector saliva.
Generally, the immune response to a protective salivary protein in vaccinated animals is
rapid and possibly acts on the parasites soon after delivery into the skin by the bite of an
infective sand fly. This is followed by the development of a stronger Leishmania-specific
immunity in saliva-vaccinated animals compared to controls. Considering that several of
the most efficacious protective molecules were identified from a proven vector of VL, we
put forward the notion that a combination vaccine that includes a Leishmania antigen and
a vector salivary protein has the potential to improve vaccine efficacy by targeting the
parasite at it most vulnerable stage just after transmission.
Keywords: visceral leishmaniasis, sand fly vectors, vector-transmission, salivary proteins as vaccines,Th1 immune
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BACKGROUND
Visceral leishmaniasis (VL), also known as kala-azar, is a systemic
vector-borne neglected disease that is fatal if left untreated. There
are an estimated 300,000 cases of VL globally with over 20,000
deaths per year, a statistic second only to malaria among para-
sitic diseases (1). Over 90% of VL cases occur in six countries
(Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan)
where about 300 million people are at risk of infection (1, 2). From
2009 to 2012, an epidemic in South Sudan caused over 28,300
cases and nearly 900 deaths1. Other areas have also been affected
by recent persistent epidemics of VL in Ethiopia and Kenya1.
Visceral leishmaniasis is caused either by Leishmania dono-
vani or L. infantum. VL caused by L. donovani is prevalent in
East Africa and the Indian sub-continent and is considered an
anthroponosis, while VL caused by L. infantum is prevalent in
South Europe, North Africa, parts of the Middle East and Latin
America (3–6). Phlebotomine sand flies are still considered the
primary and stable mode of VL transmission. Different species
of sand flies have been incriminated as vectors of VL. Phleboto-
mus argentipes is the only known vector of L. donovani in the
Indian sub-continent (7–9) and P. orientalis represents the main
sand fly species transmitting L. donovani within countries of East
Africa, Saudi Arabia, and Yemen (10, 11). On the other hand, there
are several proven vectors of VL in the Eastern Mediterranean
among which P. ariasi and P. perniciosus represent the primary
species transmitting L. infantum (12, 13), while Lutzomyia longi-
palpis is considered the primary vector of L. infantum across Latin
America (14, 15).
1www.who.int/leishmaniasis
Despite, its wide distribution and high mortality rate, there
are no available human vaccines against VL. Even with recent
improvement in treatment (16–19) and the gates initiative for the
elimination of VL from the Indian sub-continent2, there remains
a need to develop a vaccine, particularly when considering the
prevalence of infected individuals with subclinical infections that
potentially present an uncontrolled source of parasites for the sand
fly vector (20). Though the primary function of vector saliva is to
facilitate blood feeding (21), a good body of evidence has shown
that it modulates host immunity altering the outcome of infection
withLeishmania and under certain circumstances, protecting from
disease (22–24). Here, we give our perspective on the relevance of
vector saliva in the transmission of and for vaccines against VL.
VECTOR SALIVA AND PROTECTION FROM LEISHMANIASIS
Vaccination with certain immunogenic proteins in saliva of vector
sand flies confers protection from leishmaniasis (25–35). Protec-
tive molecules have mostly shared a similar property, the induction
of a delayed-type hypersensitivity (DTH) response biased toward
a Th1 profile. Importantly, animals previously exposed to saliva
or vaccinated with a Th1-biased DTH-inducing salivary protein
were protected against challenge by infected vector bites (28, 30,
35). This is significant since Peters et al. (36) showed that the innate
immune response following sand fly transmission varied signifi-
cantly from the response induced by needle challenge primarily
related to a persistence of a neutrophilic infiltrate at the site of
bite enhancing parasite virulence. Additionally, the enhanced vir-
ulence of vector-transmission was shown to abrogate protection
2www.gatesfoundation.org
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by Leishmania vaccines tested against needle challenge with para-
sites largely due to the need for a rapid effector immune response
(37). Thus, saliva-mediated protection from vector-transmitted
leishmaniasis suggests that the immune response to salivary pro-
teins is rapid enough to restrict the establishment of Leishmania
parasites following vector-challenge. Furthermore, the protection
against vector-challenge displayed by animals vaccinated with a
defined recombinant salivary protein indicates that the native
protein despite its presence among others in saliva of the vec-
tor initiated an efficient recall response upon its co-deposition in
skin with the parasites (28).
Recently, a study investigating the value of combining a protec-
tive salivary vaccine with promising Leishmania antigens tested
several combinations of PpSP15, a protective salivary protein
from P. papatasi (31, 33), with live recombinant L. tarentolae
stably expressing the cysteine proteinases CPA and CPB (38).
In both BALB/c and C57BL/6 mice, the animals primed with
PpSP15 DNA and boosted with PpSP15 DNA and live recom-
binant CPA/CPB-expressing L. tarentolae exhibited the strongest
protection against L.major infection followed by the group immu-
nized with both PpSP15 and CPA/CPB-expressing L. tarentolae
injected in independent sites (38). This study is the first to demon-
strate the enhanced protection from leishmaniasis resulting from
the inclusion of a vector salivary component to the vaccine.
The significance of vector salivary proteins in Leishmania vac-
cines is made more credible by the observed immunogenicity
of saliva in exposed humans (39–41). Gomes et al. (39) first
reported on the association between the appearance of antibod-
ies to L. longipalpis saliva and the development of a protective
cell-mediated immunity to L. chagasi. In another study, volunteers
experimentally exposed to L. longipalpis produced distinct skin
reactions at the bite site and displayed an increased frequency of
IFN-γ- and IL-10-producing T cells (40). Additionally, the authors
demonstrated that PBMC from volunteers maintained an efficient
recall response 1 year after their first exposure and produced IFN-γ
upon in vitro stimulation with saliva that was associated to a sig-
nificant reduction in macrophage infection rates with L. chagasi.
More recently, we demonstrated that the DTH response in indi-
viduals naturally exposed to bites of P. duboscqi, another vector
sand fly, persists to mid life (41). Importantly, though PBMC from
volunteers showed a Th1, Th2, or a mixed response upon in vitro
stimulation with saliva, dermal biopsies from bite sites with a DTH
response were dominated by macrophages and lymphocytes and
exhibited an abundance of IFN-γ indicative of a Th1 milieu (41).
Though more studies in humans are needed, the above results
demonstrate that repeated exposure to sand fly saliva alters the
immune response of humans to the parasites co-deposited into
the wound at the site of an infected bite.
TRANSMISSION OF VISCERAL LEISHMANIASIS AND
VECTOR SALIVA
Despite reports of vertical transmission of L. infantum (42), it is
still accepted that VL, caused by L. donovani or L. infantum, is
mostly transmitted by bite of infected phlebotomine sand flies. At
the site of bite, the sand fly deposits few parasites (43–45) alongside
saliva in the skin. Therefore, though pathology of VL is ultimately
the result of failure of internal organs, mainly the spleen and liver,
there is a vital phase early after transmission where the few para-
sites deposited in the skin are at their most vulnerable. We believe it
is at this stage that immunity to a salivary protein can potentially
exert a profound effect on the survival and ability of the para-
sites to visceralize. Studies have identified immunogenic salivary
proteins from important VL vectors that induce a distinct Th1–
DTH response predictive of protection from leishmaniasis (27,
29, 31, 46). In the only study investigating the potential of sali-
vary proteins to protect against VL, LJM19, a Th1–DTH-inducing
salivary protein from L. longipalpis, a VL vector, conferred pow-
erful protection against progressive VL in vaccinated hamsters
(29). LJM19-vaccinated animals displayed a high IFN-γ/TGF-β
ratio and inducible NOS expression in the spleen and liver associ-
ated to a controlled parasite burden and survival up to 5 months
post-infection. In contrast, controls and hamsters vaccinated with
other salivary molecules developed progressive fatal VL within the
same time frame (29). The long-term systemic protection from
L. chagasi (L. infantum) conferred by immunity to LJM19 was
likely driven by the initial immune response to LJM19 in the skin
where a distinct DTH response with high expression of IFN-γ was
observed 48 h after challenge with uninfected sand flies (29). Due
to a shorter course of infection and the ease of assessing disease
burden most studies of the protective capacity of immunogenic
salivary proteins from saliva of L. longipalpis were tested using
CL infection models producing promising results. Mice vacci-
nated with maxadilan, the vasodilator from L. longipalpis saliva
protected mice against L. major infection (34), while vaccina-
tion with LJM19, protected hamsters against infections with L.
braziliensis co-injected with saliva of the natural vector L. inter-
media (32). LJM11, another Th1–DTH-inducing salivary protein
from L. longipalpis, conferred partial protection against L. infan-
tum in hamsters (29) and a strong protection against infections
initiated by needle or vector-challenge with L. major in mice (28,
47). Table 1 provides a summary of potential salivary vaccines
identified from VL vectors to date.
Studies carried out using CL models of infection have demon-
strated that the initial immune response directed against sand fly
saliva or one of its proteins gives rise to an accelerated and potent
immune response specific to the Leishmania parasite (28, 31). The
initial saliva-specific immune response is observed as early as 2–
6 h after bite up to 1 week post-challenge (29–31, 35). By 2-weeks
post-infection, animals vaccinated with a salivary protein mount
a stronger Leishmania-specific immunity with minimized pathol-
ogy (28, 31). This supports our hypothesis that the initial immune
response to a salivary protein in the skin can potentially alter the
nature of the immune response to the parasites long-term and is
therefore relevant for protection against both CL and VL.
VECTOR SALIVA IN A VACCINE FOR VISCERAL
LEISHMANIASIS
RATIONALE
From the above, immunity to a vector salivary protein can poten-
tially have an enormous impact on progression of VL. Visceralizing
parasites are initially inoculated into the skin then navigate their
way to the viscera in a poorly understood manner. Assuming that
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Table 1 | Vaccine candidates identified from saliva of visceral leishmaniasis vectors.
Sand fly species Salivary molecule Immunogenicity Protection Animal model Reference
L. longipalpis Maxadilan Th1, IgG L. major Mouse (31)
L. longipalpis LJM19 Th1/DTH L. infantum, L. braziliensis Hamster (29, 32)
L. longipalpis LJM11 DTH, IgG L. infantum Hamster (partial) (29)
L. longipalpis LJM11 Th1/DTH, IgG2a L. major Mouse (28, 47)
L. longipalpis LJM17 Th1/DTH, IgG2a L. infantum Dog (27)
L. longipalpis LJL143 Th1/DTH, IgG2a L. infantum Dog (27)
P. ariasi ParSP01 DTH Mouse (46)
P. ariasi ParSP03 DTH, IgG2a Mouse (46)
P. ariasi ParSP25 DTH, IgG1 Mouse (46)
for a brief period of time these parasites are in the skin, low in num-
ber, and in close proximity to co-inoculated salivary proteins, a
vaccine strategy involving immunization with a Th1-inducing sali-
vary protein that would initiate a rapid immune response to itself
at the site of bite will adversely impact the vulnerable Leishmania
parasites while still in the skin. Such a vaccine could potentially
enhance the efficacy of a VL vaccine by introducing an additional
stage in which the parasites are attacked.
DIVERSITY OF VL FOCI
The complexity of VL transmission would clearly have an impact
on the design and practicality of a salivary vaccine. L. donovani,
considered an anthroponosis, is transmitted by only one species
of sand flies in the Indian sub-continent but has multiple vectors
in East Africa (7–11, 48). A similar situation exists for zoonotic
VL due to L. infantum where across Latin America transmission is
mostly by a single primary vector while along the Eastern Mediter-
ranean, over six species of sand flies have been incriminated as
major VL vectors (12–15). Foci where transmission involves mul-
tiple vectors would be more challenging compared to those where
a vaccine needs to target a single vector species. Under these con-
ditions, the future for salivary antigens is most likely in vaccines
tailored for specific regions. Nonetheless, in several of the most
important foci of VL including India, Sudan, and Latin Amer-
ica there is but one primary vector sand fly species, P. argentipes,
P. orientalis, and L. longipalpis, respectively (8–10, 14, 15, 49), a
situation where a tailored vaccine may be justified.
CHALLENGES AND SOLUTIONS
As mentioned above, in foci with a primary vector, inclusion
of a salivary protein in a leishmaniasis vaccine can potentially
enhance its efficacy. On the other hand, certain VL foci such as
those in the Eastern Mediterranean region have multiple incrim-
inated VL vectors (12, 48). For such foci, a salivary molecule with
the appropriate immunogenicity needs to have close homologs in
most sympatric vector species, creating a considerable obstacle. We
are now addressing whether priming with a salivary protein and
boosting with both the salivary antigen and a Leishmania antigen
will drive a Leishmania-specific immunity strong enough to over-
come the obstacle presented by specificity of vector salivary mol-
ecules. If successful, incorporating the best of the immunogenic
salivary proteins with the most promising Leishmania antigens
may present an opportunity for a pan leishmaniasis vaccine.
Here, we must underscore that though a robust immunity to
Leishmania driven by a preceding immunity to saliva has been
demonstrated (28, 31), it was always generated by a challenge with
virulent live parasites. It remains to be validated whether a similar
level of protective immunity can be achieved with a single anti-
gen. Considering the payback, it is a question worthy of further
exploration.
FURTHER CONSIDERATIONS
Identifying salivary molecules from VL vectors that can induce a
Th1-biased immunity in humans should be prioritized. Expres-
sion libraries of the secreted salivary proteins of several VL vec-
tors are available (46, 50–53) and high throughput expression
of endotoxin-free recombinant proteins of high purity has been
achieved (28, 54). Developing a rapid screening assay using PBMC
of healthy exposed volunteers stimulated with recombinant sali-
vary proteins from VL vectors could rapidly reveal immunogenic
antigens appropriate for further exploration as protective vaccine
candidates using animal models. Additionally, we recently devel-
oped a hamster model of vector-transmitted progressive VL (55)
that can further facilitate the prioritization of salivary vaccine can-
didates found immunogenic in humans. Here, it is important to
emphasize the need to begin the search for a vaccine candidate
using human cells (56). Multiple leishmaniasis vaccine candidates
protected various animal models but failed to protect humans
(57). This is not surprising considering that the initiation of a
Th1 cellular immunity such as that induced by salivary molecules
and required for protection against leishmaniasis implies efficient
recognition of specific antigenic epitopes by human leukocyte
antigen I (HLA-I) and HLA-II molecules for presentation to T
cells (58). However, unlike anthroponotic VL where humans are
the only vaccine target, zoonotic VL needs to target dogs as the
domestic reservoirs and the primary source of infection to sand
flies and humans (12, 48, 59, 60). Therefore, in addition to humans,
salivary molecules immunogenic in dogs such as those reported
for L. longipalpis (27), should also be considered for a canine
vaccine.
SHADES OF GRAY
Though, we tend to put Leishmania species in clear-cut cate-
gories, nature tells us otherwise. The unique polymorphic nature
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of leishmaniasis and the plasticity of Leishmania parasites con-
tinue to confound efforts toward disease control. There are
several reports where a single parasite strain commonly caus-
ing dermatotropic symptoms manifests as a visceral infection
and vice versa (61–63). Specifically, we still do not under-
stand why L. infantum, associated mainly with VL, causes only
cutaneous disease in some regions (64). Similarly, L. donovani
zymodeme MON-37, the parasite strain previously associated
exclusively with VL in India and East Africa, has been identi-
fied as the causative agent in recently established foci of CL in
Sri Lanka (65, 66). These unusual manifestations of leishma-
niasis clearly demonstrate how little we understand the factors
contributing to disease. The fact that dermotropic L. infantum
genotypes can disseminate and cause severe VL in immuno-
suppressed individuals is indicative of the importance of host
susceptibility in the outcome of infection with Leishmania par-
asites (67). But is the etiology of leishmaniasis mainly due to
host immunity or are environmental pressures, vector-derived
factors and evolution of the parasite itself equally significant?
Most likely the form of leishmaniasis contracted is the conse-
quence of all the aforementioned factors. Hence, we need to keep
an open mind in our search for vaccines and perhaps enter-
tain the option of a tailored vaccine enhanced by a salivary
component of a primary vector in foci of high morbidity and
mortality.
CONCLUSION
To date, a human vaccine against any form of leishmaniasis is non-
existent. There is strong evidence that certain proteins in sand
fly vector saliva can: (1) induce a Th1–DTH immune response;
(2) protect against both CL and VL; (3) protect against vector-
initiated CL; and (4) induce a Leishmania-specific robust immu-
nity after challenge with minimized pathology. Considering the
above, should not salivary proteins of vector sand flies be given
serious consideration as candidate components in a Leishmania
vaccine?
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